Category Archives: Rui-Ping Xiao

Hope Medicine Raises $56 Million

Hope Medicine LogoHair loss cure or treatment development related funding is really starting to boom. And most encouraging of all, China is finally joining the fray with Hope Medicine and Kintor.

Hope Medicine (China) Raises $56 Million

Until now, Kintor Pharmaceutical (China) was the main reason for the excitement. However, this weekend, the participants on this site’s hair loss chat are discussing Hope Medicine. Out of the blue, this startup company received $56 million in a Series B round of financing. Investment firms Qiming Venture Partners and Grand Flight Investment led the way.

Other investors include: HighLight Capital; Sinovation Ventures (a venture capital firm led by former Google China head Kai-Fu Lee); and Trustbridge. More here.

Phase 2 Trials Starting Soon:

“Previously, HopeMed signed an exclusive license agreement with Bayer AG on the development and commercialization of a human antibody (HMI-115) targeting the prolactin (PRL) receptor for the treatment of male and female pattern hair loss. At present, HMI-115 has completed phase I clinical trials in the European Union, with positive safety results. The global multi-center phase II clinical trials for androgenic alopecia and will soon be launched.

Ruiping Xiao
Dr. Rui-Ping Xiao

Note that I first covered Hope Medicine in my 2019 post on its partnership with Bayer in regards to the prolactin receptor. The company was founded by Dr. Rui-Ping Xiao, the dean of the College of Future Technology of Peking University. Apparently, she is also an associate editor of the New England Journal of Medicine.

The most unusual part of this story is that Hope Medicine’s official website (hopemedinc.com) has not worked for weeks. I have e-mailed several of their employees, and will update this post if I get any response.

Increasing Hair Loss Company Funding

  • This latest news comes just one month after we heard that Aneira Pharma received $25 million from Valkyrie Group.
  • South Korea’s Han Bio also seems to have received enough funding to open its new dermal papilla storage plant in May 2021.
  • In September 2020, Stemson Therapeutics received $7.5 in additional funding.